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Even interruption of energy or oxygen for a moment, can 
lead to critical impact on survival of brain. Brain relies on a 
constant perfusion to fulfill its energetic demands, in particular 
during increased neuronal activity.1 Circulation of blood has to 
deliver oxygen, glucose and other nutrients from blood to 
brain, while metabolites (ex. Lactic acid and carbon dioxide) 
must be removed. There is a tight relation between cerebral 
blood flow and neuronal activity, named neurovascular unit.2,3 
The complex interplay between neurons (terminals from the 
glutamatergic pyramidal cells and gamma-aminobutyric acid 
interneurons), astrocytes endfeet and blood vessels (endothelial 
cells, myocytes and pericytes) forms the ‘neurovascular unit’ 
which supply firstly blood to areas of neuronal activation.4,5 
Neuroimaging studies using functional magnetic resonance 
imaging and positron emission tomography also give appro-
priate help to confirm the exitence of these mechanisms.6 Re-
cently, the focus on therapy of neural diseases has shifted from 
neuronal treatment itself to vascular treatment. Furthermore, 
neurovascular unit has been magnified as target developing 
new drug for treatment of neural disease.
Agmatine, a polycationic amine, is synthesized by decarbox-
ylation of L-arginine by arginine decarboxylase (ADC). Some 
researchers have revealed that agmatine has anticonvulsant,7,8 
antineurotoxic,9-11 and antidepressant actions.12,13 In our studies, 
exogenously administered agmatine protects neurons and as-
trocytes against ischemic injury.10,14,15 Agmatine seems to mod-
ulate various functions in the heart, brain and vasculature as 
well as a number of effects on calcium homeostasis.16 Agma-
tine decreased the expression of matrix metalloproteinase-2 
(MMP-2) and MMP-9 expression induced after ischemic injury 
via the increase of endothelial nitric oxide synthase (eNOS) in 
the cerebral endothelial cells.17-19 These results reflect that ag-
matine has effect on vascular system as well as central nervous 
system.
Toxicity tests are required as basic step for developing new 
drug. Live animals are the most reliable subjects for testing 
medicines for toxicity before commercialisation. Chick chorio-
allantoic membrane (CAM) assay is considered as one of the 
model not only for determining angiogenesis at the embryonic 
stage, but also for toxicological studies.20 In the present study, 
we examined the toxicological effects of agmatine for treat-
ment of neural diseases by using the murine brain endothelial 
(bEnd.3) cells as an in vitro experimental model and CAM as-
say as an in vivo model. Our results indicate that agmatine 
doesn’t show toxic effect at all the concentrations of 50, 100 and 
200 μM in our present study.
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ObjectiveaaTo evaluate the both in vitro and in vivo toxicological effects of agmatine.
MethodsaaThe toxicity of agmatine (50, 100 and 200 μM) was determined by using Alamar Blue 
assay in murine brain endothelial (bEnd.3) cells as vitro model and chick chorioallantoic mem-
brane (CAM) assay as an in vivo model.
ResultsaaThe treatment of agmatine (50, 100 and 200 μM) showed no significant increase/de-
crease in the total cell number compared to control in the bEnd.3 cells in in vitro. The treatment 
of agmatine at three different concentrations (50, 100 and 200 μM) onto the CAM tissue for 2 
days, showed similar survival rates of chick embryo to that of the control group.
ConclusionsaaThe present results demonstrated that agmatine (50, 100 and 200 μM) doesn’t ex-
ert any toxic effect as evidenced by the above results depicting the therapeutic potential of agmatine 
via modulation of vascularization for the treatment of neural diseases.
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Materials and Methods
Cell culture
Murine brain endothelial cells (bEnd.3 cells, #CRL-2299, 
ATCC, Manassas, VA, USA) were purchased from ATCC and 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gib-
co BRL, Grand Island, NY, USA) supplemented containing 10% 
(v/v) fetal bovine serum (FBS, Hyclone Laboratories, Logan, 
UT, USA) and 100 units/mL penicillin/streptomycin (Sigma, St 
Louis, MO, USA) and were incubated at 37ºC in a humidified 
atmosphere containing 5% CO2 until they attain the confluency.
Effect of agmatine in in vitro model
The in vitro toxicity of agmatine on bEnd.3 cells was deter-
mined by Alamar Blue assay. Briefly, cells (6×103 cells/well) 
were seeded in 96-well plates, incubated for 24 h in normal me-
dia and later the cells were starved for 24 h in media added with 
0.1% FBS, and treated without or with various concentrations 
of agmatine (50, 100 and 200 μM, Sigma, St Louis, MO, USA).
Culture medium was removed from each well and was trans-
ferred to the fresh 96-well plate. The Alamar-BlueⓇ assay solu-
tion (10 μL; Invitrogen) was added to each well and cells were 
incubated for 24 h. After the incubation, the developed fluores-
cence was measured using Spectra Max Gemini EM spectro-
photometer (Molecular Devices Cooperation, Sunnyvale, CA, 
USA) with an excitation wavelength of 570 nm and an emis-
sion wavelength of 630 nm (570Ex/630Em). Fluorescence quanti-
fied was represented as 100% in control medium without ag-
matine treatment and was displayed as the relative value to that 
of control.
Effect of agmatine in in vivo model
CAM model was accepted for determining the in vivo toxic-
ity of agmatine if any.21 In brief, fertilized brown Leghorn eggs, 
obtained from Pulmuone Food Co., Seoul, Korea, were kept 
with the narrow apex down into an egg incubator at 37ºC with 
a relative humidity of 55%. After day 3.5 of incubation, 2.5 mL 
of albumen was aspirated from the eggs using 3 mL syringe 
with a sterile 18G needle through the small hole drilled at the 
blunt apex of the eggs, allowing the small chorioallantoic mem-
brane and yolk sac to drop away from the shell membrane. The 
small hole was then sealed with parafilm tape (American Na-
tional Can, Chicago, IL, USA) and eggs were placed in a static 
mode into the incubator for 1 h. After the removal of parafilm 
tape, a round window approximately 1.3 cm2 was cut out by 
forcep, and the shell membrane on the floor of the air sac was 
peeled away and covered with cellophane tape. The underlying 
CAM was accessed through this window. At day 4.5 of incuba-
tion, agmatine (50 μM) was loaded on Thermanox plastic cov-
erslip (Nalgene Nunc International, New York, NY, USA) and 
was applied onto the developing CAM surface. Two days after 
returning the chick embryo to the incubator, an appropriate vol-
ume of 10% fat emulsion (IntraliposeⓇ, 10%) was injected into 
a 6.5-day-old embryo chorioallantois. The eggs were then ob-
served under a microscope. The survival of chick embryo was 
checked by the naked eye and images of CAM was captured 
using digital camera.
The survival rate at 2 days post-treatment, was determined 
by the following formula:
Survival (%) = Aalive eggs / Atotal eggs ×100
Atotal eggs; the total number of eggs used for experiment.
Aalive eggs; the total number of eggs survival after the experi-
ment.
Statistical analysis
All experiments were expressed as mean±S.E.M. Three to 
five separate experiments were performed for each study. Data 
were analyzed by Student’s t-test or ANOVA test. p value <0.05 
were considered statistically significant.
Results
Non-toxic effect of agmatine in in vitro
The in vitro toxicity of agmatine, the number of live cell was 
quantified using the Alamar Blue colorimetric assay. The treat-
ment of agmatine (50, 100 and 200 μM) doesn’t show signifi-
cant decrease in the total cell number with the same start of cell 
seeding number at the time of experiment (6×103 cells/well). 
The percentage of total number of cells at 50, 100 and 200 μM. 
Concentration of agmatine was recorded as 99.7%, 103.6% and 
99.6%. Respectively compared to 100% cells in the control group 
(Fig. 1).
Non-toxic effect of agmatine in in vivo
In vivo toxicity of agmatine was evaluated using the CAM 
Figure 1. Agmatine did not show any toxicity on bEnd.3 cells in vi-
tro. Cells (6×103 cells/well) were seeded on 96-well plates, starved 
for 24 h in 0.1% FBS and were incubated for 24 h without (control) 
or with increasing concentration of agmatine (0, 50, 100 and 200 
μM). The cell number is given as a percentage of controls (100%). 
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model. After the treatment of 1 μL of agmatine solution con-
taining different concentrations (50, 100 and 200 μM) onto the 
CAM tissue for 2 days, the chick embryo survival was deter-
mined. Table 1 showed that survival rate (86.1%, 90.3% and 
87.2%) of chick embryo treated with agmatine (50, 100 and 200 
μM) was found to be almost compared to the control group 
(90.4%). The obtained results depicit that agmatine doesn’t ex-
ert any toxic effect until 200 μM concentration (Fig. 2).
Discussion
The blood-brain barrier, not only forms a restrictive and pro-
tective barrier between blood and the neuronal parenchyma, 
but also consists of a tightly sealed monolayer of brain endothe-
lial cells that regulate blood flow, nutrient transport, ion ho-
meostasis, clearance of toxic substrates, and various other phys-
iologic processes by the collective action of neurons, astrocytes, 
pericytes, and microglias.22,23 This interaction is referred to as 
the ‘neurovascular unit’, also named neurovascular coupling. 
Nowadays, a growing number of studies are paying attention to 
this concept.22,24-27 The importance of this concept has been sup-
ported by many recent studies showing that common signals 
and substrates underlie neuronal and vascular biology.28,29
Agmatine is a metabolite of arginine synthesized by ADC. 
Treatment of agmatine was systemically found to enhance the 
analgesic effect of morphine30-32 and inhibit tolerance to mor-
phine analgesia.33 In addition, it also has neuroprotective ef-
fects in persistent pain and neuronal injury models34 suggest-
ing that agmatine may have the pharmaco-therapeutic potential 
for the treatment of central nervous system (CNS) diseases. 
Agmatine has been shown to be packaged in synaptic vesicles 
in the brain and was spinal cord, and released upon depolar-
ization.35 With several effects on calcium homeostasis, agma-
tine seems to modulate various functions in the heart, brain 
and vasculature.16 We provided evidence that agmatine attenu-
ated expression of MMP-2 and MMP-9 expression which was 
induced by ischemic injury through the increase of eNOS in 
the cerebral endothelial cells.17-19 According to these reports, 
agmatine may have an effect on neurovascular unit. Moreover, 
agmatine (agmatine sulfate) is recently available as supplemen-
tary health food taking shape of capsule on the website of www.
amazon.com. Thus, agmatine has sufficient potential to be de-
veloped as new medicine for the treatment of neural diseases. 
It was reported that agmatine inhibited proliferation of both 
human leukemia cell lines which were in the same range as 
those determined for its inhibition of proliferation human and 
rat hepatoma cells36 and mouse kidney proximal tubule cells37 
and which are achievable in vivo. The antiproliferative effect of 
exogenous agmatine was paralleled by cell line-specific changes 
in agmatine forming and degrading enzymes which were re-
vealed by both qPCR and microarray gene expression data 
analysis.38 Inhibition of cell proliferation by agmatine has been 
shown to be associated with a reduction of the intracellular lev-
els of the polyamines.37,39 Parralled to these results, there are 
some results that agmatine usually inhibits proliferation of tu-
mor cell. Our results clearly demonstrate that treatment of ag-
matine (50, 100 and 200 μM) is found to be not toxic in murine 
bEnd.3 cells (Fig. 1) and CAM (Fig. 2, Table 1), as evidenced in 
in vitro and in vivo test. ‘Neurovascular unit’ reflects close cor-
relation with blood supply (vessel) and activation of brain (neu-
ronal activity).2 Our study for the first time provided evidence 
that agmatine until 200 μM doesn’t exert any toxic effect in 
brain endothelial cells and CAM suggesting that agmatine may 
have therapeutic potential through the modulation of vascu-
larization against neural diseases.
All together, our in vitro and in vivo studies showed non-tox-
ic effect of agmatine (50-200 μM), thus suggesting the potential 
of agmatine for the treatment of CNS diseases.
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